COMMUNIQUÉS West-GlobeNewswire

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
27/02/2026
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare [...]
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
27/02/2026
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of [...]
Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium
27/02/2026
Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UC CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. ( [...]
Tidewave Bio Appoints Prof. Alexander M.M. Eggermont, MD, PhD, as Head of Clinical Advisory Board
27/02/2026
LOS ANGELES, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a universal, biopsy-native immunotherapy platform for solid tumors, today announced the appointment of Prof. Alexander M.M [...]
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
27/02/2026
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating [...]
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
27/02/2026
Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively Total Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 [...]
OrthoPediatrics to Participate in Upcoming Conferences
27/02/2026
WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
27/02/2026
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease [...]
BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
27/02/2026
LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
27/02/2026
Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge ( [...]
ICPO and UroTeragLATAM signed a strategic agreement to accelerate Theranostics for urological cancer in Latin America
27/02/2026
The partnership strengthens education, innovation, and patient access by combining global expertise with regional leadership in precision oncology. February 27, 2026 – Wiesbaden, Germany and Miami, USA. The [...]
Trading by management and close relations of management
27/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Orion Group Financial Statement documents 2025 and Remuneration Report published
27/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET Orion Group Financial Statement documents 2025 and Remuneration Report published Orion Group's Financial Statement [...]
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
27/02/2026
Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® (vamorolone), in the [...]
QuickBurn BHB 2026: What Consumers Should Know About BHB Ketone Supplements Before Buying
27/02/2026
An informational overview of the QuickBurn BHB exogenous ketone supplement — ingredients, BHB salt research, potential side effects, ketosis claims, and what to verify before ordering. Largo, FL, Feb. 26, 2026 (GLOBE [...]
Herz P1 Smart Band 2026: What It Tracks, How It Works, and What Consumers Should Know Before Buying
27/02/2026
A 2026 Informational Overview of the Herz P1 Smart Band's Subscription-Free Health Monitoring Features, Heart Rate and HRV Tracking, Sleep Quality Analysis, Blood Oxygen and SpO2 Sensors, Stress and Temperature [...]
Keros Therapeutics Appoints Charles Newton to its Board of Directors
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
26/02/2026
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and [...]

Pages